Inosine

肌苷

Report date: 2023/02/21 20:00:25
NME

Base Information

Drug NameInosine
Drug Alias NameInosinum次黄苷次黄嘌呤核苷InosinaRiboxinum +[6] 
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Nucleoside analogues
Mechanisms of ActionBeta-nerve growth factor stimulants
TargetsBeta-nerve growth factor
Therapy Area/IndicationsDiabetes Mellitus, Type 2Skin DiseasesAnemia +[9] 
Global Approved IndicationsHepatitis
Approved Indications in ChinaHepatitis
Original Approved Country/TerritoryMainland China
Original Approved DateN/A
Country/TerritoryUnited StatesPuerto RicoRussian Federation +[5] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesN/A
China Registration ClassN/A

Develop Information

Active CompaniesFudan UniversityXuzhou Ryen Pharmaceutical Co Ltd
Inactive CompaniesHarvard School Of Public HealthNational Center For Complementary And Integrative HealthTheracos Inc +[5] 
Active IndicationsSkin DiseasesAnemiaCardiovascular Diseases +[5] 
Inactive IndicationsDiabetes Mellitus, Type 2Parkinson DiseaseMultiple Sclerosis, Relapsing-Remitting +[4] 

Other Information

ATC CodeD06BB05G01AX02S01XA10
Related LinksWikipediaDrugBankKEGG